137 related articles for article (PubMed ID: 35916466)
21. SMN1 dosage analysis in spinal muscular atrophy from India.
Kesari A; Rennert H; Leonard DG; Mittal B
BMC Med Genet; 2005 May; 6():22. PubMed ID: 15910686
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Reference Materials for Spinal Muscular Atrophy Genetic Testing: A Genetic Testing Reference Materials Coordination Program Collaborative Project.
Prior TW; Bayrak-Toydemir P; Lynnes TC; Mao R; Metcalf JD; Muralidharan K; Iwata-Otsubo A; Pham HT; Pratt VM; Qureshi S; Requesens D; Shen J; Vetrini F; Kalman L
J Mol Diagn; 2021 Jan; 23(1):103-110. PubMed ID: 33197628
[TBL] [Abstract][Full Text] [Related]
23. Large-scale population screening for spinal muscular atrophy: clinical implications.
Ben-Shachar S; Orr-Urtreger A; Bardugo E; Shomrat R; Yaron Y
Genet Med; 2011 Feb; 13(2):110-4. PubMed ID: 21233719
[TBL] [Abstract][Full Text] [Related]
24. Incidental molecular diagnoses and heterozygous risk alleles in a carrier screening cohort.
Reiner J; Rosenblum LS; Xin W; Zhou Z; Zhu H; Leach N
Genet Med; 2023 Feb; 25(2):100317. PubMed ID: 36459106
[TBL] [Abstract][Full Text] [Related]
25. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: Two years' experience in one medical center.
Wheeler PG; Smith R; Dorkin H; Parad RB; Comeau AM; Bianchi DW
Genet Med; 2001; 3(6):411-5. PubMed ID: 11715005
[TBL] [Abstract][Full Text] [Related]
26. The clinical utility of a risk-modifying SNP to detect carriers for spinal muscular atrophy with increased sensitivity.
Ware G; Miller C; Jones D; Avenarius M
Mol Genet Genomic Med; 2022 Apr; 10(4):e1897. PubMed ID: 35289093
[TBL] [Abstract][Full Text] [Related]
27. ACOG Committee Opinion No. 469: Carrier screening for fragile X syndrome.
Obstet Gynecol; 2010 Oct; 116(4):1008-1010. PubMed ID: 20859177
[TBL] [Abstract][Full Text] [Related]
28. Carrier testing for spinal muscular atrophy.
Gitlin JM; Fischbeck K; Crawford TO; Cwik V; Fleischman A; Gonye K; Heine D; Hobby K; Kaufmann P; Keiles S; MacKenzie A; Musci T; Prior T; Lloyd-Puryear M; Sugarman EA; Terry SF; Urv T; Wang C; Watson M; Yaron Y; Frosst P; Howell RR
Genet Med; 2010 Oct; 12(10):621-2. PubMed ID: 20808230
[TBL] [Abstract][Full Text] [Related]
29. Counseling for personal health implications identified during reproductive genetic carrier screening.
Gbur S; Mauney L; Gray KJ; Wilkins-Haug L; Guseh S
Prenat Diagn; 2021 Oct; 41(11):1460-1466. PubMed ID: 34426984
[TBL] [Abstract][Full Text] [Related]
30. NGS-based expanded carrier screening for genetic disorders in North Indian population reveals unexpected results - a pilot study.
Singh K; Bijarnia-Mahay S; Ramprasad VL; Puri RD; Nair S; Sharda S; Saxena R; Kohli S; Kulshreshtha S; Ganguli I; Gujral K; Verma IC
BMC Med Genet; 2020 Nov; 21(1):216. PubMed ID: 33138774
[TBL] [Abstract][Full Text] [Related]
31. "I'm Healthy, It's Not Going To Be Me": Exploring experiences of carriers identified through a population reproductive genetic carrier screening panel in Australia.
Beard CA; Amor DJ; Di Pietro L; Archibald AD
Am J Med Genet A; 2016 Aug; 170(8):2052-9. PubMed ID: 27150953
[TBL] [Abstract][Full Text] [Related]
32. Genetic Carrier Screening in the Twenty-first Century.
Yao R; Goetzinger KR
Clin Lab Med; 2016 Jun; 36(2):277-88. PubMed ID: 27235912
[TBL] [Abstract][Full Text] [Related]
33. Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome and spinal muscular atrophy: patterns of community and healthcare provider participation in a Victorian screening program.
Leibowitz R; Lewis S; Emery J; Massie J; Smith M; Delatycki M; Archibald A
Aust J Prim Health; 2022 Dec; 28(6):580-587. PubMed ID: 36192111
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Parental Understanding of Positive Newborn Screening Results and Carrier Status for Cystic Fibrosis with the use of a Short Educational Video.
Temme R; Gruber A; Johnson M; Read L; Lu Y; McNamara J
J Genet Couns; 2015 Jun; 24(3):473-81. PubMed ID: 25236483
[TBL] [Abstract][Full Text] [Related]
35. Carrier screening for cystic fibrosis: a perinatal perspective.
Demsey SA
J Perinat Neonatal Nurs; 1999 Sep; 13(2):14-26. PubMed ID: 10818851
[TBL] [Abstract][Full Text] [Related]
36. FMR1 premutation frequency in a large, ethnically diverse population referred for carrier testing.
Owens KM; Dohany L; Holland C; DaRe J; Mann T; Settler C; Longman RE
Am J Med Genet A; 2018 Jun; 176(6):1304-1308. PubMed ID: 29603880
[TBL] [Abstract][Full Text] [Related]
37. Clinical validity and utility of preconception expanded carrier screening for the management of reproductive genetic risk in IVF and general population.
Capalbo A; Fabiani M; Caroselli S; Poli M; Girardi L; Patassini C; Favero F; Cimadomo D; Vaiarelli A; Simon C; Rienzi LF; Ubaldi FM
Hum Reprod; 2021 Jun; 36(7):2050-2061. PubMed ID: 34021342
[TBL] [Abstract][Full Text] [Related]
38. [Carrier screening for spinal muscular atrophy in 4719 pregnant women in Shanghai region].
Gong B; Zhang L; Hou YP; Hu HY; Li HC; Tan MY; Chen J; Yu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):670-2. PubMed ID: 24327144
[TBL] [Abstract][Full Text] [Related]
39. [Results of carrier screening for Spinal muscular atrophy among 35 145 reproductive-aged individuals from Dongguan region].
Zhao Y; Lou J; Fu Y; Dai Y; Liang Q; Sun M; Tan J; Liu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Jun; 40(6):655-660. PubMed ID: 37211998
[TBL] [Abstract][Full Text] [Related]
40. Cystic Fibrosis testing among Arab-Americans.
Wei S; Feldman GL; Monaghan KG
Genet Med; 2006 Apr; 8(4):255-8. PubMed ID: 16617247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
